IN THE DISCLOSURE

No changes.

IN THE CLAIMS

Please amend the following claims.

---

2. (Amended) [A] The process of Claim 1 comprising the steps of:

i) a [A]dding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent and mixing in the liquid state;

ii) e [E]vaporating the solvent to obtain a dried material, and

iii) f [F]urther processing the dried material into the solid pharmaceutical composition.

3. (Amended) [A] The process of Claim 2 wherein, before the solvent is evaporated, the liquid is filtered to remove unreacted alkaline magnesium compound.

4. (Amended) [A] The process of Claim 2 or 3 wherein the solvent is evaporated by spray-drying.

5. (Amended) [A] The process of Claim 1 comprising the steps of:

i) adding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent;

ii) using the resultant solution or suspension to wet granulate other excipients to obtain a wet mass;

iii) drying the wet mass to obtain a dried mass; and

iv) further processing the dried mass into the solid pharmaceutical composition.

6. (Amended) [A] The process of Claim 1 comprising the steps of:

i) adding the alkaline magnesium compound to solvent;

ii) using the resulting solution or suspension to wet granulate a mixture of the moexipril or acid addition salt thereof and one or more excipients to obtain a wet mass;

iii) drying the wet mass to obtain a dried mass; and

iv) further processing the dried mass into the solid pharmaceutical composition.

7. (Amended) [A] The process of Claim 1 comprising the steps of:

i) adding the moexipril or acid addition salt thereof to solvent;

ii) using the resultant solution or suspension to wet granulate a mixture of the alkaline magnesium compound and one or more other excipients to obtain wet mass;

iii) drying the wet mass to obtain a dried mass; and

iv) further processing the dried mass into the solid pharmaceutical composition.

8. (Amended) [A] The process of Claim 1 comprising the steps of:

i) mixing the moexipril or acid addition salt thereof and alkaline magnesium compound with one or more other excipients;

ii) adding a solvent and mixing to obtain a wet mass;

iii) drying the wet mass to obtain a dry mass; and

iv) further processing the dried mass into the solid pharmaceutical composition.

9. (Amended) [A] The process of any one of Claims [1 to 8] 1, 2, 3, 5, 6, 7, or 8 where the solvent is selected from a group of solvents comprising water, an organic solvent, acetone, or combinations thereof.

10. (Amended) [A] The process of any one of Claims [1 to 8] 1, 2, 3, 5, 6, 7, or 8 wherein the moexipril or acid addition salt thereof is moexipril hydrochloride.

11. (Amended) [A] The process of any one of Claims [1 to 8] 1, 2, 3, 5, 6, 7, or 8 wherein the alkaline magnesium compound is selected from the group of compounds comprising magnesium hydroxide, magnesium oxide, magnesium carbonate, or the magnesium salt of a weak acid.

12. (Amended) [A] The process of any one of Claims [1 to 8] 1, 2, 3, 5, 6, 7, or 8 wherein the percentage of the moexipril or acid addition salt converted to moexipril magnesium is substantially greater than about 80%.

13. (Amended) [A] The process of [any of] Claim 12 wherein the percentage of the moexipril or acid addition salt thereof converted to moexipril magnesium is substantially greater than 90%.

Please add the following claims.

15. The process of Claim 4 where the solvent is selected from a group of solvents comprising water, an organic solvent, acetone, or combinations thereof.

16. The process of Claim 4 wherein the moexipril or acid addition salt thereof is moexipril hydrochloride.

17. The process of Claim 4 wherein the alkaline magnesium compound is selected from the group of compounds comprising magnesium hydroxide, magnesium oxide, magnesium carbonate, or the magnesium salt of a weak acid.

18. The process of Claim 4 wherein the percentage of the moexipril or acid addition salt converted to moexipril magnesium is substantially greater than about 80%.

REMARKS

Further to the Filing Receipt received from the United States Patent Office, a copy of which is enclosed herewith, large entity status was not given to the above-mentioned application, although Applicant requested large entity status upon filing. A copy of Applicant's filing letter dated March 15, 2001 is enclosed for the Examiner's reference.